[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653908":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":37,"studyPopulation":16,"armGroups":38,"interventions":50,"overallOfficials":16,"centralContacts":56,"locations":66,"responsibleParty":80,"collaborators":16,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":16,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":106,"whyStopped":16,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of composite cardiovascular events","Cumulative incidence of composite cardiovascular events. The composite cardiovascular and cerebrovascular events are defined as follows:\n\n* Stroke (either ischemic or hemorrhagic)\n* Acute Coronary Syndrome (myocardial infarction or unstable angina)\n* Vascular Revascularization (cerebrovascular, cardiovascular, peripheral vascular, or aortic)\n* Cardiovascular-related death","From enrollment until 36months",[14,17,19,21,23,25,28],{"measure":15,"description":16,"timeFrame":12},"Percentage change in LDL-C (from baseline)",null,{"measure":18,"description":16,"timeFrame":12},"Changes in total cholesterol, HDL-C, and triglycerides",{"measure":20,"description":16,"timeFrame":12},"Proportion of patients achieving target LDL-C",{"measure":22,"description":16,"timeFrame":12},"Changes in the degree of cerebrovascular stenosis",{"measure":24,"description":16,"timeFrame":12},"Occurrence of new cerebrovascular stenosis",{"measure":26,"description":27,"timeFrame":12},"Assessment of quality of life using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire","The EQ-5D-5L descriptive system assesses health status across five dimensions: mobility, self-care, usual activities, pain\u002Fdiscomfort, and anxiety\u002Fdepression. Each dimension is rated on a 5-level scale from 1 to 5, with 1 indicating no problems and 5 indicating extreme problems or inability to perform the activity. Lower scores indicate better health status.",{"measure":29,"description":30,"timeFrame":12},"Individual cardiovascular events","* Ischemic stroke\n* Hemorrhagic stroke\n* Transient Ischemic Attack (TIA)\n* Myocardial infarction\n* Coronary revascularization (Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting)\n* All-cause mortality",{"allocation":32,"interventionModel":33,"interventionModelDescription":16,"primaryPurpose":34,"observationalModel":16,"timePerspective":16,"maskingInfo":35},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":36,"maskingDescription":16,"whoMasked":16},"NONE","1. Background and Rationale Asymptomatic intracranial atherosclerotic stenosis (aICAS) is increasingly recognized as a clinically significant condition associated with an elevated risk of ischemic stroke and systemic vascular events. Despite this, there is a paucity of randomized evidence defining optimal lipid-lowering strategies in this population. Current lipid management guidelines are predominantly informed by studies in symptomatic atherosclerosis or coronary artery disease and may not be directly generalizable to patients with aICAS.\n\n   This study is designed to test the hypothesis that intensive lipid-lowering therapy targeting LDL70 mg\u002FdL provides superior reduction in vascular events compared with a standard LDL-C target of \\\u003C100 mg\u002FdL.\n2. Study Design This study is a multicenter, prospective, randomized, open-label, active-controlled clinical trial.\n\n   A total of 1,626 participants will be enrolled and randomized in a 1:1 ratio to one of two treatment arms. Randomization will be performed using a centralized web-based system and stratified according to intracranial stenosis burden, baseline statin use, and the presence of diabetes mellitus.\n3. Intervention Participants assigned to the moderate-intensity group will receive lipid-lowering therapy titrated to achieve and maintain LDL-C levels \\\u003C100 mg\u002FdL.\n\n   Participants assigned to the intensive treatment group will receive statin-based therapy with additional lipid-lowering agents as needed to achieve and maintain LDL-C levels \\\u003C70 mg\u002FdL.\n4. Follow-up and Assessments The enrollment period is expected to span 2 years. Participants will undergo a core follow-up period of 3 years, with study visits at 3, 12, 24, and 36 months. Extended follow-up will continue annually for up to 7 years.",[39,45],{"label":40,"type":41,"description":42,"interventionNames":43},"High-Intensity Lipid-Lowering Therapy","EXPERIMENTAL","The group will receive medication to maintain LDL-C levels below 70 mg\u002FdL throughout the study period. There are no restrictions on the type of lipid-lowering agents used; all medications may be appropriately adjusted based on the participant's condition, provided they are administered within the approved dosage and administration guidelines.",[44],"Drug: Lipid Lowering Treatment",{"label":46,"type":47,"description":48,"interventionNames":49},"Moderate-Intensity Lipid-Lowering Therapy","ACTIVE_COMPARATOR","The group will receive medication to maintain LDL-C levels below 100 mg\u002FdL throughout the study period. There are no restrictions on the type of lipid-lowering agents used; all medications may be appropriately adjusted based on the participant's condition, provided they are administered within the approved dosage and administration guidelines.",[44],[51],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":16},"DRUG","Lipid Lowering Treatment","Lipid-lowering therapy will be administered using one or more lipid-lowering agents, as clinically appropriate. The type, dosage, and combination of lipid-lowering agents may be selected and adjusted by the treating investigator according to the participant's clinical condition, in accordance with relevant clinical practice guidelines and approved prescribing information.",[40,46],[57,62],{"name":58,"role":59,"phone":60,"phoneExt":16,"email":61},"Woo-Keun Seo, Ph.D","CONTACT","82-2-3410-0799","mcastenosis@gmail.com",{"name":63,"role":59,"phone":64,"phoneExt":16,"email":65},"Seoha Kim","82-2-2148-7668","seoha88.kim@samsung.com",[67],{"facility":5,"status":16,"city":68,"state":16,"zip":69,"country":70,"countryCode":16,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Seoul","06351","South Korea",{"type":72,"coordinates":73},"Point",[74,75],126.9784,37.566,{"lat":75,"lon":74},[78,79],{"name":58,"role":59,"phone":60,"phoneExt":16,"email":61},{"name":63,"role":59,"phone":16,"phoneExt":16,"email":65},{"type":81,"investigatorFullName":82,"investigatorTitle":83,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"SPONSOR_INVESTIGATOR","Woo-Keun Seo","Professor","100653908","moderate-versus-intensive-lipid-lowering-for-events-in-asymptomatic-intracranial-stenosis-100653908",false,"NCT07791823","Moderate Versus Intensive Lipid-lowering for Events in Asymptomatic Intracranial Stenosis","Effect of Moderate- vs High-Intensity Lipid-Lowering Therapy in Patients With Asymptomatic Intracranial Atherosclerotic Disease: A Multicenter, Prospective, Randomized, Open-Label Trial","MILES","Inclusion Criteria:\n\n1. Adults aged 19 to 80 years at the time of screening\n2. Presence of ≥50% stenosis in at least one major intracranial artery confirmed within 12 months prior to randomization by magnetic resonance angiography (MRA), computed tomography angiography (CTA), or conventional cerebral angiography.(Target vessels include: Middle cerebral artery (M1 or M2 segment), Anterior cerebral artery (A1 or A2 segment), Posterior cerebral artery (P1 or P2 segment), Basilar artery, Vertebral artery (V4 segment)) Stenosis severity must be assessed according to the WASID (Warfarin-Aspirin Symptomatic Intracranial Disease) method\n3. Baseline low-density lipoprotein cholesterol (LDL-C) level of 100-190 mg\u002FdL, or current use of lipid-lowering therapy\n4. Presence of at least one of the following vascular risk factors:\n\n   * Hypertension (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current use of antihypertensive medication)\n   * Diabetes mellitus (fasting plasma glucose ≥126 mg\u002FdL or ongoing antidiabetic treatment)\n   * Current smoking\n   * Family history of premature coronary artery disease (onset age \\\u003C55 years in men or \\\u003C65 years in women)\n   * Chronic kidney disease (estimated glomerular filtration rate \\[eGFR\\] \\\u003C60 mL\u002Fmin\u002F1.73 m²)\n\nExclusion Criteria:\n\n1. Cerebrovascular Pathologies\n\n   * Prior history of symptomatic ischemic stroke or transient ischemic attack(TIA)\n   * Previous cerebrovascular interventions, including intracranial or extracranial stenting or carotid endarterectomy\n   * History of non-traumatic intracranial hemorrhage (ICH)\n   * Presence of cerebral aneurysms or arteriovenous malformations (AVM)\n   * Confirmed diagnosis of Moyamoya disease\n2. Cardiovascular Comorbidities\n\n   * Unstable angina pectoris or myocardial infarction (MI) within the preceding 6 months\n   * Advanced heart failure, categorized as NYHA Class III or IV.\n   * Severe valvular heart disease\n   * Atrial fibrillation requiring chronic oral anticoagulation (CHA2DS2-VASc score ≥ 2, or persistent\u002Fpermanent atrial fibrillation)\n3. Contraindications to Lipid-Lowering Therapy\n\n   * Known hypersensitivity to statins or ezetimibe\n   * History of severe statin-associated muscle symptoms (SAMS), including rhabdomyolysis\n   * Confirmed familial hypercholesterolemia\n4. Active hepatic disease within 1 month prior to screening, or serum transaminases (ALT\u002FAST) exceeding 3 times the upper limit of normal (ULN)\n5. Type 2 diabetes mellitus requiring long-term insulin therapy, or those with established target organ damage (e.g., diabetic nephropathy, proliferative retinopathy, or clinically significant neuropathy), Type 1 diabetes mellitus with a disease duration of 20 years or more\n6. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m²\n7. Women who are currently pregnant or breastfeeding\n8. Patients currently enrolled in other interventional clinical trials.","ALL","19 Years","80 Years",{"count":96,"type":97},1626,"ESTIMATED","INTERVENTIONAL",[100],"NA","It is designed to compare two different strengths of cholesterol-lowering treatment in patients who have narrowing of blood vessels inside the brain (intracranial atherosclerosis) but do not currently have symptoms such as stroke.\n\nThe purpose of this study is to find out whether more intensive cholesterol-lowering treatment provides better protection against future vascular events, such as stroke, compared to moderate treatment. Cholesterol, especially LDL cholesterol, is known to contribute to the buildup of plaques in blood vessels, which can lead to serious complications.\n\nParticipants in this study are adults diagnosed with asymptomatic intracranial arterial narrowing. Because they do not yet have symptoms, this study aims to prevent future problems before they occur.\n\nThis is a multicenter study, meaning it is conducted at multiple hospitals. It is prospective, so participants are followed over time. It is also randomized, which means participants are assigned by chance (like flipping a coin) into one of two groups. One group receives moderate-intensity cholesterol-lowering therapy, while the other receives high-intensity therapy. The study is open-label, meaning both doctors and patients know which treatment is being given.\n\nParticipants will undergo regular follow-up visits during the study. These visits may include blood tests, imaging studies, and clinical assessments to monitor cholesterol levels, blood vessel condition, and overall health. The researchers will track whether participants experience any vascular events, such as stroke or transient ischemic attack (TIA).\n\nThe study will also monitor safety. Any side effects or adverse reactions to the medications will be carefully recorded. This ensures that both the effectiveness and safety of the treatments are evaluated.",[103],"Intracranial Atherosclerosis ICAS",[105],"AICAS","NOT_YET_RECRUITING","2026-08-28",{"date":109,"type":110},"2026-09-01","ACTUAL",{"date":112,"type":97},"2026-09-30",{"date":114,"type":97},"2031-09-30",{"name":82,"class":6},1]